Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

19 août 2020 07h00 HE | Source: PolyPid Ltd.

PolyPid Ltd. Provides Corporate Update and Reports Second Quarter 2020 Financial Results

Initiated Phase 3 SHIELD I Trial for D-PLEX100 in Abdominal Surgery and Received Fast Track Designation for D-PLEX100 from FDA Presented Positive Phase 2 Results of D-PLEX100 for Prevention of...
05 août 2020 16h01 HE | Source: PolyPid Ltd.

PolyPid to Report Second Quarter 2020 Financial Results and Operational Highlights on August 19, 2020

PETAH TIKVA, Israel, Aug. 05, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and...
03 août 2020 07h00 HE | Source: PolyPid Ltd.

PolyPid Granted Fast Track Designation from FDA for D-PLEX₁₀₀ for Prevention of Surgical Site Infections in Abdominal Surgery

PETAH TIKVA, Israel, Aug. 03, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and...
27 juil. 2020 07h00 HE | Source: PolyPid Ltd.

PolyPid to Present Phase 2 Results of D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Surgery at the American Society of Colon and Rectal Surgeons 2020 Annual Scientific Conference Recorded Sessions

PETAH TIKVA, Israel, July 27, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and...